What is Leerink Partnrs’ Estimate for AQST FY2024 Earnings?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities researchers at Leerink Partnrs raised their FY2024 EPS estimates for shares of Aquestive Therapeutics in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings per share of ($0.47) for the year, up from their prior estimate of ($0.50). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Aquestive Therapeutics’ Q4 2024 earnings at ($0.14) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the previous year, the company earned ($0.03) earnings per share.

Several other brokerages also recently issued reports on AQST. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday. Finally, Leerink Partners upped their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $9.80.

Aquestive Therapeutics Stock Up 7.5 %

Shares of NASDAQ AQST opened at $5.46 on Friday. Aquestive Therapeutics has a 12 month low of $1.55 and a 12 month high of $6.23. The company has a market cap of $497.84 million, a P/E ratio of -12.13 and a beta of 2.82. The business’s 50 day moving average is $4.94 and its two-hundred day moving average is $3.84.

Institutional Trading of Aquestive Therapeutics

Several institutional investors have recently made changes to their positions in the business. Intech Investment Management LLC bought a new position in Aquestive Therapeutics during the third quarter worth about $90,000. GSA Capital Partners LLP boosted its stake in Aquestive Therapeutics by 525.5% in the 3rd quarter. GSA Capital Partners LLP now owns 137,151 shares of the company’s stock valued at $683,000 after buying an additional 115,223 shares in the last quarter. Chartwell Investment Partners LLC bought a new stake in Aquestive Therapeutics in the third quarter valued at $535,000. Cahill Wealth Management LLC raised its stake in Aquestive Therapeutics by 20.6% during the third quarter. Cahill Wealth Management LLC now owns 142,941 shares of the company’s stock worth $712,000 after acquiring an additional 24,380 shares in the last quarter. Finally, Harvey Capital Management Inc. bought a new position in shares of Aquestive Therapeutics during the third quarter valued at $88,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.